Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)

Breast Cancer Research and Treatment

Volumn 107, Issue 1, 2008, Pages 87-94

  Takei, Hiroyuki ^a   Suemasu, Kimito ^a   Inoue, Kenichi ^a   Saito, Tsuyoshi ^b   Okubo, Katsuhiko ^c   Koh, Junichi ^d   Sato, Kazuhiko ^e   Tsuda, Hitoshi ^e   Kurosumi, Masafumi ^a   Tabei, Toshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b SAITAMA RED CROSS HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Aromatase inhibitor; Clinical response; Exemestane; Neoadjuvant therapy; Pathological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EXEMESTANE; HORMONE RECEPTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYTICAL EQUIPMENT; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOMAMMOGRAPHY; FATIGUE; FEMALE; GENITAL BLEEDING; HEMATOLOGIC DISEASE; HOT FLUSH; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAMMOGRAPHY; MASTECTOMY; MEDICAL SOCIETY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 36549059551     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9529-4     Document Type: Article

References (33)

1. Wolff AC, Davidson NE (2000) Primary systemic therapy in operable breast cancer. J Clin Oncol 18:1558-1569
2. Freedman OC, Verma S, Clemons MJ (2005) Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31:1-17
3. Strasser-Weippl K, Goss PE (2005) Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23:1751-1759
4. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767
5. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase II study of the International Letrozole Breast Cancer Study Group. J Clin Oncol 19:2596-2606
6. Paridaens R, Therasse P, Dirix L et al (2004) First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients-a randomized phase III trial of the EORTC Breast Group [abstract 515]. Proc Am Soc Clin Oncol 23:6
7. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131-2139
8. Baum M, Budzar AU, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810
9. The Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
10. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
11. Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of the ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
12. Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147
13. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
14. Dixon JM, Renshaw L, Bellamy C et al (2000) The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center trial. Clin Cancer Res 6:2229-2235
15. Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116
16. Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527-1532
17. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816
18. Gil MJ, Barnadas A, Cirera L et al (2004) Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter; results of a Spanish multicenter phase II trial [abstract 603]. Proc Am Soc Clin Oncol 23:27
19. Tubiana-Hulin M, Spyratos F, Becette V et al (2003) Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer [abstract 443]. Breast Cancer Res Treat 82:S106
20. Krainick U, Astner A, Jonat W, Wallwiener D (2003) Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer-final results of the German Neoadjuvant Aromasin Initiative (GENARI) [abstract 239]. Breast Cancer Res Treat 82:S55
21. Semiglazov VF, Semiglazov VV, Ivanov VG et al (2003) Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4N1-2M0) [abstract 111]. Breast Cancer Res Treat 82:S22
22. Tovey S, Dunne B, Witton CJ et al (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835-4842
23. Dowsett M, Cuzick J, Wale C et al (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23:7512-7517
24. Bundred NJ (2005) The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 93:S23-S27
25. Goss PE, Qi S, Cheung AM et al (2004) Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 10:5717-5723
26. Kurosumi M, Akiyama F, Iwase T et al (2001) Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 8:1-2
27. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
28. Cancer Therapy Evaluation Program. Common Toxicity Criteria version 2.0 (1999) National Cancer Institute. http://www.fda.gov/cder/cancer/toxicityframe. htm. Cited 30 November 2006
29. Kuroi K, Toi M, Tsuda H et al (2006) Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13:38-48
30. Llombart A, Galán A, Fuster C et al (2006) Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PR[+] operable breast cancer [abstract 362]. Eur J Cancer 4:154
31. Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261
32. Cui X, Schiff R, Arpino G et al (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721-7735
33. Goss P, Ingle J, Tu D (2006) NCIC CTG MA17: updated analysis on disease free survival (DFS) according to the estrogen receptor and progesterone receptor status of the primary tumor [abstract 350]. Eur J Cancer 4:149-150